Company Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1993 |
| IPO Date | Nov 14, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Thane Wettig |
Contact Details
Address: 350 Bay Street, Suite 10 #6009 San Francisco, California 94133 United States | |
| Phone | 415 978 1200 |
| Website | fibrogen.com |
Stock Details
| Ticker Symbol | FGEN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921299 |
| CUSIP Number | 31572Q881 |
| ISIN Number | US31572Q8814 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer and Director |
| David DeLucia | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 5, 2025 | 8-K | Current Report |
| Sep 2, 2025 | 8-K | Current Report |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 15, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jul 14, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |